This post was originally published on this site
(Reuters) – The UK drug regulator added an extremely rare nerve-damaging disorder, Guillain-Barré syndrome (GBS), as a very rare side effect of the AstraZeneca (NASDAQ:AZN) COVID-19 vaccine, updates on the agency’s website showed on Thursday.
Medicines and Healthcare products Regulatory Agency’s (MHRA) decision comes after the European medicines agency added GBS as a possible side-effect last month.
